AbbVie (NYSE:ABBV) Issues Earnings Results, Misses Estimates By $0.82 EPS

AbbVie (NYSE:ABBV) announced its quarterly earnings results on Friday. The company reported $2.16 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82), RTT News reports. AbbVie had a net margin of 9.22% and a return on equity of 244.01%. During the same period in the prior year, the business earned $2.79 EPS. AbbVie updated its FY 2025 guidance to 12.120-12.320 EPS.

AbbVie Stock Performance

AbbVie stock traded up $8.97 during trading hours on Friday, hitting $184.62. 6,478,440 shares of the stock traded hands, compared to its average volume of 5,935,105. The company has a debt-to-equity ratio of 9.64, a current ratio of 0.65 and a quick ratio of 0.54. The firm’s 50 day moving average price is $176.43 and its 200-day moving average price is $184.84. The stock has a market capitalization of $326.26 billion, a price-to-earnings ratio of 64.10, a P/E/G ratio of 1.77 and a beta of 0.58. AbbVie has a 1 year low of $153.58 and a 1 year high of $207.32.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Daiwa Capital Markets downgraded AbbVie from an “outperform” rating to a “neutral” rating and set a $180.00 price objective on the stock. in a research report on Thursday, December 5th. Wells Fargo & Company increased their price target on AbbVie to $195.00 and gave the stock a “buy” rating in a report on Tuesday, November 19th. Leerink Partners upgraded AbbVie from a “market perform” rating to an “outperform” rating and set a $206.00 price target on the stock in a report on Friday, November 22nd. Piper Sandler increased their price target on AbbVie from $212.00 to $220.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. Finally, Sanford C. Bernstein initiated coverage on AbbVie in a report on Thursday, October 17th. They issued a “market perform” rating and a $203.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $205.00.

Insider Buying and Selling at AbbVie

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the company’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $172.24, for a total value of $310,032.00. Following the completion of the transaction, the senior vice president now owns 6,983 shares of the company’s stock, valued at approximately $1,202,751.92. This represents a 20.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.25% of the company’s stock.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.